XTL Biopharmaceuticals Ltd.

ILA 1.40As of Sun 8 Nov 2026, 12:00 UTC

TASE:XTLBHealthcare

Country Israel

PE (Fwd) •••

TSR 10Y CAGR (21.77%)

Div yield —

ROE (29.30%)

Biotechnology

Beta (5Y) 0.47

PE TTM —

TSR TTM (63.16%)

Mkt cap ILS 18.54M

ROIC (34.43%)

SE Grade™

—

Value

Quality

Moat

Consensus

Reference

ILA 1.65

17.89%

43.26%

Hold 12|7|11|12|11

TTM

FYE 31 Dec USD

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

5Y

10Y

Peers

0.958

Revenue$M

2.967

3.121

3.159

3.199

3.336

3.382

3.437

3.534

3.613

3.686

1.012

2.02%

2.67%

20

15.03

Revenue growth%

21.57

20.69

23.22

25.62

28.38

31.11

32.99

32.23

35.07

36.40

10.54

32.99

29.74

57

15.98

Gross margin%

25.82

27.26

25.63

27.07

26.77

26.29

28.25

30.03

28.10

28.36

4.74

28.25

27.17

50

12.12

Operating margin%

26.11

24.78

24.93

24.66

27.21

27.71

27.83

30.15

30.21

31.41

18.14

30.15

27.46

46

24.42

Net margin%

10.33

7.51

10.18

10.29

11.78

10.56

9.38

11.30

8.56

6.84

24.50

9.38

10.24

69

26.08

P/E ratio (avg)x

36.51

35.15

32.52

28.42

30.29

30.49

29.30

28.99

30.01

29.23

20.70

29.30

30.15

80

20.52

EV/EBITx

20.75

21.77

25.03

23.52

23.00

26.20

25.91

25.04

24.94

27.87

9.155

25.91

24.98

23

10.68

FCF yield (avg)%

22.54

25.02

22.31

23.61

26.34

29.24

29.00

26.77

25.13

27.18

20.73

27.18

25.73

11

27.23

FCF margin%

9.82

11.50

13.84

14.97

15.31

14.93

14.58

12.10

9.25

11.89

26.73

12.10

12.97

41

0.985

FCF / Net incomex

1.152

1.139

1.178

1.178

1.246

1.423

1.368

1.358

1.381

1.477

0.285

1.381

1.302

45

2.24

ROIC%

3.18

2.69

1.41

2.24

3.81

2.71

2.93

5.29

2.52

1.02

18.31

2.71

2.70

35

11.64

Return on equity%

18.80

21.01

20.42

22.68

20.24

22.44

21.59

18.78

17.55

16.57

16.20

18.78

20.33

46

2.79

Return on assets%

15.61

13.62

12.58

13.33

10.91

13.65

13.31

14.20

12.78

15.32

15.69

13.65

13.47

55

—

EPS$

—

—

—

—

—

—

—

—

—

—

—

(1.71%)

0.64%

—

2.95

EPS growth%

26.29

26.53

27.98

29.76

32.15

31.55

30.18

29.81

31.85

34.33

5.59

31.55

30.00

15

—

Bookvalue per sh$

—

—

—

—

—

—

—

—

—

—

—

(7.40%)

(6.40%)

—

—

FCF per share$

—

—

—

—

—

—

—

—

—

—

—

(4.68%)

(5.32%)

—

—

Dividend per sh$

—

—

—

—

—

—

—

—

—

—

—

0.02%

1.05%

—

15.44

Div yield (avg)%

21.55

23.79

22.71

24.79

22.19

20.19

18.26

18.39

16.04

15.90

5.22

18.26

20.87

81

8.17

Payout ratio%

17.53

18.58

19.23

19.12

18.09

15.80

15.14

14.83

15.12

17.67

15.00

15.14

17.60

85

1.329

Shares (diluted)B

1.802

1.821

1.711

1.616

1.481

1.536

1.711

1.766

1.986

2.272

1.331

8.94%

3.77%

80

16.07

Buyback yield%

28.80

28.96

30.91

28.90

30.48

31.69

32.33

29.60

32.05

33.91

22.51

32.05

30.70

73

0.662

D/E ratiox

0.205

0.205

0.197

0.213

0.201

0.195

0.197

0.225

0.224

0.217

1.525

0.217

0.205

19

0.632

Enterprise value$M

0.710

0.797

0.948

1.016

1.093

1.087

1.227

1.388

1.348

1.464

3.842

6.03%

9.33%

45

3.197

LT debt$M

1.793

1.624

1.670

1.551

1.375

1.321

1.192

1.139

1.228

1.233

3.256

(2.16%)

(4.48%)

25

Peers (US$5.793M)

Cap (US$)

PE

CollPlant Biotechnolog…

7.507M

—

Can-Fite BioPharma Ltd.

5.096M

—

4.606M

—

Longeveron Inc.

5.771M

—

Capital

TTM

5Y

10Y

Leveragex

2.476

—

—

EBIT/Intx

0.447

0.373

0.346

Own earn%

14.18

(5.19)

6.47

Sh yield%

31.51

49.81

51.24

Owners

Insiders/Inst%

1.16

53.41

Short interest%

0.94

SBC / revenue%

1.82

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

22

Op margin range%

25–31

$1 testx

—

Incr. ROIC%

12

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$3.686M

2.67%

1.00×

Cost of revenue

$1.696M

2.79%

1.01×

Operating expenses

$0.780M

2.34%

0.97×